ADHD Medications and Long-Term Cardiovascular Risk: What a Large Study Found

Why This Study Matters

Many adults considering ADHD medication wonder about long-term safety, particularly regarding heart health. Since stimulant medications can affect heart rate and blood pressure, understanding whether long-term exposure increases cardiovascular risk is an important question for both patients and clinicians.

What the Study Looked At

This large population-based cohort study examined whether cumulative exposure to ADHD medications was associated with long-term cardiovascular disease risk (14 year follow-up). Researchers analyzed national health registry data from hundreds of thousands of individuals diagnosed with ADHD and tracked medication exposure over time. The goal was to determine whether longer cumulative use of ADHD medications was associated with higher rates of cardiovascular conditions such as hypertension, arrhythmias, or other heart-related disorders.

Key Findings

  • ADHD medications may be associated with modest increases in blood pressure–related conditions over long periods.

  • major cardiovascular events (e,g. heart attack, stroke) were not clearly elevated in this study.

  • Routine clinical practice—screening for cardiac history and monitoring blood pressure and heart rate—remains appropriate.

My Take

Studies like this are important because they help clinicians better understand long-term safety. One key point is that the absolute risk increase reported in this study was relatively small. For many adults with ADHD, the benefits of treatment—improved functioning, productivity, and quality of life—can be substantial. In practice, careful screening for cardiovascular risk factors and periodic monitoring of blood pressure and heart rate are standard parts of treatment. As with most medications in medicine, the decision to use ADHD medication involves weighing potential benefits against potential risks for each individual.

Source
Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D'Onofrio BM, Brikell I, Kuja-Halkola R, Lichtenstein P, Johnell K, Larsson H, Chang Z. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294